ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Emergency Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,673Medicare Part D Prescriptions Filled, Including Refills

Rank: 3 out of 264

$444K Total Retail Price of All Prescriptions

Rank: 3 out of 264

486 Patients Receiving at Least One Drug in Part D
90%Patients 65 Years and Older
20% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Louisiana
Lower avg

Schedule Two
Controlled Substances

2% of this provider’s 486 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

6% of this provider’s 486 patients filled at least one prescription for a schedule three drug, compared to an average of 33%.

Risky Drugs to Seniors

2% of this provider’s 7,929 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 0%.

Brand Name Drugs

22% of this provider’s prescriptions were for brand-name drugs, compared to an average of 11%.

Prescription Price

$51 was the average price of a prescription from this provider, compared to $37 among peers.

Prescriptions per Patient

18 is the average number of prescriptions (including refills) per patient, compared to an average of 3.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Louisiana
AMLODIPINE BESYLATE 422 388 1 3
SIMVASTATIN 383 368 2 9
LEVOTHYROXINE SODIUM 366 353 3 7
LISINOPRIL 307 268 4 2
HYDROCHLOROTHIAZIDE 295 282 5 15
OMEPRAZOLE 275 250 6 5
METOPROLOL SUCCINATE 224 201 7 22
METFORMIN HCL 199 184 8 6
ZOLPIDEM TARTRATE 182 166 9 19
PRAVASTATIN SODIUM 163 158 10 17
SERTRALINE HCL 163 153 10 25
METOPROLOL TARTRATE 130 124 12 16
ATENOLOL 118 111 13 57
FLUTICASONE PROPIONATE 117 93 14 32
ATORVASTATIN CALCIUM 114 112 15 21
LISINOPRIL-HYDROCHLOROTHIAZIDE 111 106 16 12
GABAPENTIN 110 76 17 11
FUROSEMIDE 109 94 18 8
CLOPIDOGREL 107 103 19 41
HYDROCODONE-ACETAMINOPHEN 92 71 S3 20 1
NEXIUM 87 87 21 13
CARVEDILOL 83 69 22 23
PANTOPRAZOLE SODIUM 83 79 22 33
ALLOPURINOL 82 78 24 31
RAMIPRIL 82 82 24 106
AMITRIPTYLINE HCL 81 55 R 26 34
BENAZEPRIL HCL 81 81 26 107
LOSARTAN POTASSIUM 80 71 28 45
ALENDRONATE SODIUM 80 75 28 46
DONEPEZIL HCL 80 69 28 30
TAMSULOSIN HCL 79 78 31 39
POTASSIUM CHLORIDE 78 59 32 14
NAMENDA 71 71 33 29
SYNTHROID 64 63 34 121
GLYBURIDE 62 62 R 35 90
PLAVIX 62 60 35 66
TRIAMTERENE-HCTZ 60 60 37 85
AMLODIPINE BESYLATE-BENAZEPRIL 52 48 38 38
MELOXICAM 52 52 38 26
DOXAZOSIN MESYLATE 51 41 40 143
ESCITALOPRAM OXALATE 51 50 40 59
LOSARTAN-HYDROCHLOROTHIAZIDE 51 51 40 143
CITALOPRAM HBR 51 50 40 28
VENLAFAXINE HCL ER 50 27 44 76
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on April 20, 2010.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.